Neurocrine Biosciences, Inc. is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies for a range of neurological, endocrine, and psychiatric conditions. Its established portfolio offers solutions for conditions such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids. Foremost among its commercialized offerings is INGREZZA, a VMAT2 inhibitor specifically indicated for treating tardive dyskinesia.